Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024)

Simply Wall St

May 16, 2025

Zentalis Pharmaceuticals (NASDAQ:ZNTL) First Quarter 2025 Results

Key Financial Results

Net loss: US$48.3m (down from US$10.1m profit in 1Q 2024).
US$0.67 loss per share (down from US$0.14 profit in 1Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

earnings-and-revenue-history — NasdaqGM:ZNTL Earnings and Revenue History May 16th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zentalis Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You still need to take note of risks, for example - Zentalis Pharmaceuticals has 2 warning signs we think you should be aware of.

If you're looking to trade Zentalis Pharmaceuticals, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Zentalis Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.